List of investigational borderline personality disorder drugs

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources.

This is a list of investigational borderline personality disorder drugs, or drugs that are currently under development for clinical use in the treatment of borderline personality disorder (BPD) but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

This list was last comprehensively updated in March 2025. It is likely to become outdated with time.

Under development

Phase 3

• Quetiapine (Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator) ^[1]

Phase 2

• BI-1358894 – transient receptor potential channel TRPC4 and TRPC5 inhibitor ^[2]
• Lumateperone – atypical antipsychotic (non-selective monoamine receptor modulator) ^[3]
• Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen ^[4]
• Vafidemstat (ORY-2001) – lysine-specific demethylase 1 (LSD1; KDM1A) and monoamine oxidase B (MAO-B) inhibitor ^[5]

Not under development

Development discontinued

• Brexpiprazole (Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator) ^[6]
• Citalopram (Celexa) – selective serotonin reuptake inhibitor ^[7]

Formal development never or not yet started

• Other serotonergic psychedelics and entactogens (e.g., LSD, midomafetamine (MDMA)) ^{[8] [9]}

Clinically used drugs

Off-label drugs

• Anticonvulsants (e.g., lamotrigine, topiramate, valproic acid) ^{[10] [11] [12]}
• Antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs)) ^{[10] [12]}
• Atypical antipsychotics (e.g., aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone) ^{[13] [11] [12] [14]}
• Benzodiazepines (e.g., alprazolam, clonazepam, diazepam, lorazepam) ^{[15] [16]}
• Mood stabilizers (e.g., lithium) ^[17]
• Omega-3 fatty acids ^[11]
• Sedative antihistamines (e.g., promethazine) ^[16]

See also

• List of investigational drugs
• List of investigational aggression drugs

References

1. "Quetiapine - AstraZeneca". AdisInsight. 6 December 2023. Retrieved 8 March 2025.
2. "BI 1358894". AdisInsight. 23 February 2024. Retrieved 8 March 2025.
3. "Delving into the Latest Updates on Lumateperone Tosylate with Synapse". Synapse. 28 February 2025. Retrieved 8 March 2025.
4. "Delving into the Latest Updates on Psilocybin with Synapse". Synapse. 13 February 2025. Retrieved 16 February 2025.
5. "Vafidemstat - Oryzon Genomics". AdisInsight. 6 December 2024. Retrieved 24 February 2025.
6. "Brexpiprazole - Lundbeck/Otsuka". AdisInsight. 14 January 2025. Retrieved 8 March 2025.
7. "Delving into the Latest Updates on Citalopram Hydrobromide with Synapse". Synapse. 23 January 2025. Retrieved 8 March 2025.
8. Yao Y, Guo D, Lu TS, Liu FL, Huang SH, Diao MQ, Li SX, Zhang XJ, Kosten TR, Shi J, Bao YP, Lu L, Han Y (May 2024). "Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis". Psychiatry Res. 335: 115886. doi:10.1016/j.psychres.2024.115886. PMID   38574699.
9. Traynor JM, Roberts DE, Ross S, Zeifman R, Choi-Kain L (October 2022). "MDMA-Assisted Psychotherapy for Borderline Personality Disorder". Focus (Am Psychiatr Publ). 20 (4): 358–367. doi:10.1176/appi.focus.20220056. PMC   10187385 . PMID   37200873.
10. Stoffers-Winterling J, Storebø OJ, Lieb K (June 2020). "Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies". Curr Psychiatry Rep. 22 (8): 37. doi:10.1007/s11920-020-01164-1. PMC   7275094 . PMID   32504127.
11. Ripoll LH (January 2012). "Clinical psychopharmacology of borderline personality disorder: an update on the available evidence in light of the Diagnostic and Statistical Manual of Mental Disorders - 5". Curr Opin Psychiatry. 25 (1): 52–58. doi:10.1097/YCO.0b013e32834c3f19. PMID   22037092.
12. Mercer D, Douglass AB, Links PS (April 2009). "Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms". J Pers Disord. 23 (2): 156–174. doi:10.1521/pedi.2009.23.2.156. PMID   19379093.
13. Griffiths K, Velichkova N, Quadt L, Berni J (September 2024). "Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis". Psychiatry Res Commun. 4 (3). doi:10.1016/j.psycom.2024.100187. PMC   11413517 . PMID   39309544.
14. Grootens KP, Verkes RJ (January 2005). "Emerging evidence for the use of atypical antipsychotics in borderline personality disorder". Pharmacopsychiatry. 38 (1): 20–23. doi:10.1055/s-2005-837767. PMID   15706462.
15. Pascual JC, Arias L, Soler J (June 2023). "Pharmacological Management of Borderline Personality Disorder and Common Comorbidities". CNS Drugs. 37 (6): 489–497. doi:10.1007/s40263-023-01015-6. PMC   10276775 . PMID   37256484.
16. Leichsenring F, Heim N, Leweke F, Spitzer C, Steinert C, Kernberg OF (February 2023). "Borderline Personality Disorder: A Review". JAMA. 329 (8): 670–679. doi:10.1001/jama.2023.0589. PMID   36853245.
17. Bellino S, Paradiso E, Bogetto F (2008). "Efficacy and tolerability of pharmacotherapies for borderline personality disorder". CNS Drugs. 22 (8): 671–692. doi:10.2165/00023210-200822080-00005. PMID   18601305.

External links

• AdisInsight - Springer